Abstract
Nadofaragene firadenovec (awaiting regulatory approval) and pembrolizumab are bladder-sparing alternatives for treating Bacillus Calmette–Guérin (BCG)-unresponsive, high-risk non-muscle invasive bladder cancer (NMIBC). Cost-utility and value of information (VOI) analyses of these treatments, compared with a hypothetical treatment comparator based on approved and investigational therapies, were conducted from a United States health system perspective.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
